this hypothesis, but the lack of a similar correlation for IgG and IgA suggests that other factors may be important, one possibility being a general increase in immune responsiveness.
The prevalence of autoantibodies in the present series belies the generally accepted view that they are rarely, if ever, found in alcoholic cirrhosis.'6 They were less prevalent in our patients than in those with chronic active hepatitis'7 but more prevalent than in the controls. Furthermore, although the titres were generally low, similar titres are found in some patients with chronic active hepatitis. '7 We have suggested that the higher prevalence of HLA-B8 in chronic active hepatitis occurs because this antigen is linked to genes that promote abnormally raised and prolonged antibody responses.'0 While HLA-B8 is also fairly prevalent (450,) in alcoholic cirrhosis, the association is not as great as in HBsAgnegative chronic active hepatitis, in which more than 600' of the patients have this histocompatibility antigen.'8 Similarly, the higher prevalence of serum autoantibodies and raised immunoglobulin concentrations is not as striking as in chronic active hepatitis,'7 and thus immunologically these two groups of patients seem to differ in the intensity of their immune responses. The biological significance of the absence of HLA-A28 is not clear, but this antigen was also not found in any of our patients with HBsAg-negative chronic active hepatitis8 nor in those originally reported by MacKay and Morris. 9 In spite of these genetic similarities there are obvious clinical and histological differences between the two diseases, and there are probably qualitative, as well as quantitative, differences in their immunopathogenesis. Thus, T lymphocytes were recently found to predominate (91 00) in the portal tract infiltrates in alcoholic liver disease, whereas the proportion in patients with chronic active hepatitis seemed to be much lower.'8 Possibly these T lymphocytes are reacting to the changes that alcohol may induce in hepatocyte membranes'9 and are actively implicated in the destruction of these changed liver cells. The spontaneous fibrinolytic activity, local fibrinolytic activity during standardised venous occlusion of the arms, and fibrinolytic activity ofthe vessel walls increased significantly after treatment with ethyloestrenol 8 mg/day for three months. No further increase occurred after three months, and ethyloestrenol 4 mg/day had no effect. No values rose significantly in the patients with a normal fibrinolytic system. One patient suffered a recurrence within three months of treatment, before the fibrinolytic system became normal. In one patient the fibrinolytic defect reappeared after 10 months in spite of continued treatment. Two of the three women of fertile age developed irregular cycles and intermenstrual bleeding, which disappeared when the treatment was withdrawn.
No other side effects were observed.
Introduction
A defective fibrinolytic defence mechanism (decreased fibrinolytic activator activity in the vein walls or a defective release of fibrinolytic activator from the vein walls, or both) has been found in about 70% of patients with recurrent deep venous thrombosis (DVT) and no known predisposing condition. ' Fearnley et all showed that phenformin (100 mg/day) combined with ethyloestrenol (8 mg/day) increased the spontaneous fibrinolytic activity of the blood. The same treatment was later shown to increase the fibrinolytic activity in the vein walls when given to healthy volunteers.3 Furthermore, when given to patients with recurrent DVT and a defective fibrinolytic defence mechanism treatment with phenformin and ethyloestrenol increases the spontaneous fibrinolytic activity, the capacity to release fibrinolytic activator during venous occlusion of the arms, and the fibrinolytic activity of the vessel walls. 4 Anabolic steroids alone have also been shown to increase the venous plasma fibrinolytic reserve.5 6 The side effects of phenformin are, however, serious, so the effect on the fibrinolytic system of ethyloestrenol alone in doses of 8 mg/day or 4 mg/day was studied in 49 patients with recurrent DVT.
Patients and methods
The 49 patients (34 men, 15 women) had either decreased fibrinolytic activity in the vessel walls or a decreased release mechanism, or both. Their ages ranged from 22 to 78 years (mean 51 3), and 10 were aged under 40. None of the patients had any coexisting disease. Forty-five of the patients had had phlebographically verified recurrent DVT during the five years before the first examination (two to five thrombotic episodes), and five also had had pulmonary embolism. The remaining four patients had arterial thrombosis (thrombi were present in the internal carotid artery or middle cerebral artery or the patients suffered transient ischaemic attacks or peripheral arterial ischaemia). On admission to the trial 10 of the patients were receiving dicoumarol prophylactically, and this was continued until the fibrinolytic system returned to normal. Six men had been treated with the combination of phenformin and ethyloestrenol4 for one to four years.
The patients were examined on average three months after the end of their last thrombotic episode. Lach patient was examined on two consecutive days and 21 were re-examined just before the beginning of treatment to check that the defect was consistent. All patients were then examined after three, six, and 10 to 17 months of treatment (table I) . Fifteen patients (aged 35-82 years; mean 64 7 years) with a normal fibrinolytic defence mechanism were also studied. Four had had recurrent DVT (two to five episodes each) and the remaining 11 had severe arteriosclerosis. These patients were given ethyloestrenol 8 mg/day and were re-examined after three, six, and 12 months.
Laboratory methods-The spontaneous fibrinolytic activity of resuspended euglobulin precipitate of plasma was measured on unheated fibrin plates7 (normal range: 0-70 mm2).
Venous occlusion was performed as described. 
Results
The spontaneous fibrinolytic activity of circulating blood was significantly increased after three months' treatment (P < 0-001) and 1) . After 10-17 months' treatment the further increase was hardly significant (P < 0 02). The release capacity of fibrinolytic activators from the vessel walls, measured as the local fibrinolytic activity obtained after venous occlusion, is given in fig 2. In 18 out of 31 patients the release capacity was defective before treatment (<158 mm2). After three months' treatment with ethyloestrenol 8 mg/day only four patients still had a decreased release capacity and after 10-17 months' treatment only two of the 15 examined patients had a decreased release capacity (fig 2; table II). After three months' treatment with ethyloestrenol 8 mg/day a significant increase (P < 0 01) was obtained. No further increase was seen (P > 0 05) during treatment. No significant increase occurred in any of the 15 patients who had a normal release capacity before the treatment (see table III ). No significant increase in the fibrinolytic capacity was observed after treatment with 4 mg/day over three to 17 months (table II) . The fibrinolytic activity in the vessel walls was decreased ( < 6 arbitrary units) in 19 out of 30 patients before treatment with ethyloestrenol 8 mg/day (fig 3) . The mean level of the fibrinolytic activity rose significantly after three months' treatment (P < 0-001) and the mean remained at about 7 arbitrary units throughout the observation period. After three months' treatment three patients out of 26 examined still had a decreased vessel wall fibrinolytic activity, and after 10-17 months four out of 14 still showed a decreased level (<6 arbitrary units) (table II) .
After treatment with 4 mg/day (fig 3) vessel wall activity did not increase significantly until after 10 to 15 months (P <001). Before treatment eight out of 12 patients showed decreased activity in the vessel walls and four out of 10 showed decreased activity after three months' treatment (P > 0 05). After 10 to 15 months' treatment none of the four patients examined showed a decreased vessel wall activity (table II) .
The patients who had earlier been treated with phenformin and ethyloestrenol (8 mg/day) all had a normal fibrinolytic system when phenformin was withdrawn. During the subsequent treatment with only ethyloestrenol (8 mg/day) they remained normal.
Spontaneous fibrinolytic activity, release capacity after venous occlusion, and fibrinolytic activity in the vessel walls did not increase significantly in patients with a normal fibrinolytic defence mechanism (table III) . No significant changes of the fibrinogen were observed during treatment (P > 0 05).
One recurrence occurred within three months of treatment, when the fibrinolytic system was not yet normal. One patient developed suspected resistance. After three months' treatment both fibrinolytic activator activity in the vessel walls and release capacity became normal. At re-examination 11 and 16 months after the start of treatment a decreased vessel wall activity was found.
Side effects-Two of the three women of fertile age developed irregular menstrual bleeding and one of them also claimed to have put on weight. Because of these side effects the treatment was withdrawn, and the menstrual bleeding pattern returned to normal. No other side effects were observed.
Discussion
Prophylactic treatment with a combination of phenformin and ethyloestrenol normalises the defective fibrinolytic system in patients with a decreased fibrinolytic activity in the vessel walls or a defective release capacity of fibrinolytic activators from the vessel walls, or both. 4 Severe No recurrence occurred in the patients with a fibrinolytic system that had returned to normal, which might suggest that the effective treatment that results in a normal fibrinolytic system is effective as thrombosis prophylaxis in patients with a fibrinolytic defect.
